Search research articles
Contact Us
Filters
Showing results (281-290 of 326) with videos related to
Page
of 33
Sort By:
Breast Cancer Research and Treatment
|
July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Martin Schuler, Ahmad Awada, Philipp Harter, et al.
Geburtshilfe Und Frauenheilkunde
|
June 13, 2025
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
Diana Lüftner, Maggie Banys-Paluchowski, Andreas D Hartkopf, et al.
Breast Cancer Research and Treatment
|
November 1, 2016
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
Nadia Harbeck, Steffen Saupe, Elke Jäger, et al.
Anti-Cancer Drugs
|
March 16, 2019
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)
Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, et al.
Trials
|
May 17, 2023
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
Tom Degenhardt, Peter A Fasching, Diana Lüftner, et al.
Frontiers in Oncology
|
August 4, 2023
Effects of intermittent fasting on quality of life tolerance of chemotherapy in patients with gynecological cancers: study protocol of a randomized-controlled multi-center trial
Mona Wanda Schmidt, Walburgis Brenner, Susanne Gebhard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
Gunter von Minckwitz, Volker Möbus, Andreas Schneeweiss, et al.
BMC Medicine
|
October 8, 2024
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER<sup>+</sup> breast cancer
Philipp Zimmer, Tobias Esser, Diana Lueftner, et al.
Nature Communications
|
June 8, 2019
Extremely high conductivity observed in the triple point topological metal MoP
Nitesh Kumar, Yan Sun, Michael Nicklas, et al.
Nature Communications
|
September 10, 2017
Direct measurement of individual phonon lifetimes in the clathrate compound Ba<sub>7.81</sub>Ge<sub>40.67</sub>Au<sub>5.33</sub>
Pierre-François Lory, Stéphane Pailhès, Valentina M Giordano, et al.
Page
of 33
Search research articles
Search
Showing results (281-290 of 326) with videos related to
Sort By:
Page
of 33
Breast Cancer Research and Treatment
|
July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Martin Schuler, Ahmad Awada, Philipp Harter, et al.
Geburtshilfe Und Frauenheilkunde
|
June 13, 2025
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
Diana Lüftner, Maggie Banys-Paluchowski, Andreas D Hartkopf, et al.
Breast Cancer Research and Treatment
|
November 1, 2016
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
Nadia Harbeck, Steffen Saupe, Elke Jäger, et al.
Anti-Cancer Drugs
|
March 16, 2019
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)
Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, et al.
Trials
|
May 17, 2023
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
Tom Degenhardt, Peter A Fasching, Diana Lüftner, et al.
Frontiers in Oncology
|
August 4, 2023
Effects of intermittent fasting on quality of life tolerance of chemotherapy in patients with gynecological cancers: study protocol of a randomized-controlled multi-center trial
Mona Wanda Schmidt, Walburgis Brenner, Susanne Gebhard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
Gunter von Minckwitz, Volker Möbus, Andreas Schneeweiss, et al.
BMC Medicine
|
October 8, 2024
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER<sup>+</sup> breast cancer
Philipp Zimmer, Tobias Esser, Diana Lueftner, et al.
Nature Communications
|
June 8, 2019
Extremely high conductivity observed in the triple point topological metal MoP
Nitesh Kumar, Yan Sun, Michael Nicklas, et al.
Nature Communications
|
September 10, 2017
Direct measurement of individual phonon lifetimes in the clathrate compound Ba<sub>7.81</sub>Ge<sub>40.67</sub>Au<sub>5.33</sub>
Pierre-François Lory, Stéphane Pailhès, Valentina M Giordano, et al.
Page
of 33